Literature DB >> 8733963

Vascular MR contrast enhancement in cerebrovascular disease.

M Essig1, R von Kummer, T Egelhof, R Winter, K Sartor.   

Abstract

PURPOSE: To determine the significance of vascular enhancement in stroke patients with and without permanent neurologic deficit.
METHODS: We prospectively studied two groups of patients with spin-echo MR imaging before and after injection of gadopentetate dimeglumine. In the patients in group 1 (12 women, 22 men; age range, 32 to 76 years), who had permanent neurologic deficit caused by recent ischemic brain infarction, we obtained 3 to 13 serial MR images during follow-up examination. Group 2 consisted of 26 patients (14 women, 12 men; age range, 54 to 81 years) with transient neurologic deficit caused by angiographically proved high-grade stenosis or occlusion of the internal carotid artery.
RESULTS: Vascular enhancement was present in 59% of patients in group 1 and in 65% of patients of group 2. In group 1, the frequency of vascular enhancement declined steadily over several weeks, but it was still present in single cases even after 3 months. Vascular enhancement correlated positively with the extent of brain infarction in group 1 and with the degree of carotid stenosis in group 2.
CONCLUSION: Vascular enhancement as shown by MR imaging may herald ischemic brain infarction and could persist over several weeks in areas that show collateral flow after infarction has occurred.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733963      PMCID: PMC8337505     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  18 in total

1.  "Ivy sign" on fluid-attenuated inversion-recovery images in childhood moyamoya disease.

Authors:  M Maeda; C Tsuchida
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

2.  Intraarterial signal on fluid-attenuated inversion recovery images: a measure of hemodynamic stress?

Authors:  R L Wolf
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

3.  Transient partial amnesia complicating cardiac and peripheral arteriography with nonionic contrast medium.

Authors:  Altan Yildiz; Esin Yencilek; F Demir Apaydin; Meltem Nass Duce; Caner Ozer; Ahmet Atalay
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

Review 4.  Systematic review of methods for assessing leptomeningeal collateral flow.

Authors:  F McVerry; D S Liebeskind; K W Muir
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-01       Impact factor: 3.825

5.  Leptomeningeal collaterals in acute ischemic stroke.

Authors:  Nauman Tariq; Rakesh Khatri
Journal:  J Vasc Interv Neurol       Date:  2008-10

6.  [Transient monoparesis of the right arm after carotid artery stenting].

Authors:  M Meier-Meitinger; M Lell; M Uder
Journal:  Radiologe       Date:  2011-04       Impact factor: 0.635

7.  Evolution of MR contrast enhancement patterns during the first week after acute ischemic stroke.

Authors:  J O Karonen; P L Partanen; R L Vanninen; P A Vainio; H J Aronen
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

8.  Relationship between vascular enhancement, cerebral hemodynamics, and MR angiography in cases of acute stroke.

Authors:  P Pantano; D Toni; F Caramia; A Falcou; M Fiorelli; C Argentino; L M Fantozzi; L Bozzao
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

9.  The Association between FLAIR Vascular Hyperintensity and Stroke Outcome Varies with Time from Onset.

Authors:  W J Shang; H B Chen; L M Shu; H Q Liao; X Y Huang; S Xiao; H Hong
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

10.  Accuracy of pre- and postcontrast 3D time-of-flight MR angiography in patients with acute ischemic stroke: correlation with catheter angiography.

Authors:  H Ishimaru; M Ochi; M Morikawa; H Takahata; Y Matsuoka; T Koshiishi; T Fujimoto; A Egawa; K Mitarai; T Murakami; M Uetani
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.